Overview

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Status:
Completed
Trial end date:
2014-07-28
Target enrollment:
Participant gender:
Summary
This is a Phase I study with a conditional cohort expansion phase to evaluate the feasibility of, and to obtain preliminary efficacy data about, pretreatment with Azacytidine (AZA) for 5 days followed by fludarabine/cytarabine chemotherapy regimen in pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients who are refractory to primary treatment or who relapsed.
Phase:
Phase 1
Details
Lead Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium
Collaborators:
Gateway for Cancer Research
University of Southern California
Treatments:
Azacitidine
Cytarabine
Fludarabine
Fludarabine phosphate
Methotrexate
Vidarabine